Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment

Transection of the oesophagus for bleeding oesophageal varices

R. N. H. Pugh, I M Murray-Lyon, J L Dawson et al. · British journal of surgery · 1973 · 8K citations

Medicine, Surgery, Emergency Surgery +8

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

George L. Bakris, Rajiv Agarwal, Juliana C.N. Chan et al. · JAMA · 2015 · 688 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

Roger K. Verbeeck · European Journal of Clinical Pharmacology · 2008 · 638 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

Bertram Pitt, Piotr Ponikowski, Mihai Gheorghiade et al. · European Heart Journal · 2013 · 575 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease

Gerasimos Filippatos, Stefan D. Anker, Michael Böhm et al. · European Heart Journal · 2016 · 429 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14